277 related articles for article (PubMed ID: 31071311)
41. MECHANISTIC INSIGHTS INTO OSTEOPOROSIS IN PATIENTS WITH LIPODYSTROPHY AND REVIEW OF THE LITERATURE.
Huang L; Shi H; Zhou X
Endocr Pract; 2017 Jul; 23(7):857-862. PubMed ID: 28448764
[TBL] [Abstract][Full Text] [Related]
42. [Abdominal adipose area, serum adiponectin and leptin levels of nonalcoholic fatty liver disease in elderly males.].
Tao T; Wu L; Shen BB; Zhao YJ
Zhonghua Gan Zang Bing Za Zhi; 2009 Feb; 17(2):120-3. PubMed ID: 19254460
[TBL] [Abstract][Full Text] [Related]
43. Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome.
Verkauskiene R; Dollfus C; Levine M; Faye A; Deghmoun S; Houang M; Chevenne D; Bresson JL; Blanche S; Lévy-Marchal C
Pediatr Res; 2006 Aug; 60(2):225-30. PubMed ID: 16864709
[TBL] [Abstract][Full Text] [Related]
44. [Lipodystrophy. Mechanisms, clinical presentation, therapy].
Miehle K; Stumvoll M; Fasshauer M
Internist (Berl); 2011 Apr; 52(4):362, 364-6, 368-70 passim. PubMed ID: 21424143
[TBL] [Abstract][Full Text] [Related]
45. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy.
Moran SA; Patten N; Young JR; Cochran E; Sebring N; Reynolds J; Premkumar A; Depaoli AM; Skarulis MC; Oral EA; Gorden P
Metabolism; 2004 Apr; 53(4):513-9. PubMed ID: 15045701
[TBL] [Abstract][Full Text] [Related]
46. Molecular and Cellular Bases of Lipodystrophy Syndromes.
Zammouri J; Vatier C; Capel E; Auclair M; Storey-London C; Bismuth E; Mosbah H; Donadille B; Janmaat S; Fève B; Jéru I; Vigouroux C
Front Endocrinol (Lausanne); 2021; 12():803189. PubMed ID: 35046902
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.
Schäffler A; Schölmerich J; Büchler C
Nat Clin Pract Gastroenterol Hepatol; 2005 Jun; 2(6):273-80. PubMed ID: 16265231
[TBL] [Abstract][Full Text] [Related]
48. Steatohepatitis associated with limb lipodystrophy.
Powell EE; Searle J; Mortimer R
Gastroenterology; 1989 Oct; 97(4):1022-4. PubMed ID: 2777026
[TBL] [Abstract][Full Text] [Related]
49. Mouse models of inherited lipodystrophy.
Savage DB
Dis Model Mech; 2009; 2(11-12):554-62. PubMed ID: 19892886
[TBL] [Abstract][Full Text] [Related]
50. Practice guideline for lipodystrophy syndromes-clinically important diseases of the Japan Endocrine Society (JES).
Tanaka T; Kusakabe T; Ebihara K; Aizawa-Abe M; Aotani D; Yorifuji T; Satoh M; Ogawa Y; Nakao K
Endocr J; 2021 Sep; 68(9):1027-1042. PubMed ID: 34373417
[No Abstract] [Full Text] [Related]
51. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
[TBL] [Abstract][Full Text] [Related]
52. Correlation of Leptin, Adiponectin, and Resistin Levels in Different Types of Lipodystrophy in HIV/AIDS Patients.
Srdic D; Khawla AM; Soldatovic I; Nikolic J; Jevtovic D; Nair D; Dragovic G
Metab Syndr Relat Disord; 2017 Apr; 15(3):153-159. PubMed ID: 28339344
[TBL] [Abstract][Full Text] [Related]
53. Leptin-replacement therapy for lipodystrophy.
Oral EA; Simha V; Ruiz E; Andewelt A; Premkumar A; Snell P; Wagner AJ; DePaoli AM; Reitman ML; Taylor SI; Gorden P; Garg A
N Engl J Med; 2002 Feb; 346(8):570-8. PubMed ID: 11856796
[TBL] [Abstract][Full Text] [Related]
54. Adipocyte-derived hormone levels in HIV lipodystrophy.
Kosmiski L; Kuritzkes D; Lichtenstein K; Eckel R
Antivir Ther; 2003 Feb; 8(1):9-15. PubMed ID: 12713059
[TBL] [Abstract][Full Text] [Related]
55. [Lipodystrophies].
Fardet L; Vigouroux C; Capeau J
Rev Med Interne; 2013 Oct; 34(10):614-22. PubMed ID: 23287278
[TBL] [Abstract][Full Text] [Related]
56. [Leptin, adiponectin, lipodystrophic and severe insulin resistance syndromes].
Vatier C; Jéru I; Fellahi S; Capeau J; Bastard JP; Vigouroux C;
Ann Biol Clin (Paris); 2020 Jun; 78(3):261-264. PubMed ID: 32420889
[TBL] [Abstract][Full Text] [Related]
57. The clinical utility of leptin therapy in metabolic dysfunction.
Park JY; Gavrilova O; Gorden P
Minerva Endocrinol; 2006 Jun; 31(2):125-31. PubMed ID: 16682936
[TBL] [Abstract][Full Text] [Related]
58. Plasma adiponectin is decreased in nonalcoholic fatty liver disease.
Pagano C; Soardo G; Esposito W; Fallo F; Basan L; Donnini D; Federspil G; Sechi LA; Vettor R
Eur J Endocrinol; 2005 Jan; 152(1):113-8. PubMed ID: 15762194
[TBL] [Abstract][Full Text] [Related]
59. Treatment Options for Lipodystrophy in Children.
Mainieri F; Tagi VM; Chiarelli F
Front Endocrinol (Lausanne); 2022; 13():879979. PubMed ID: 35600578
[TBL] [Abstract][Full Text] [Related]
60. Effects of leptin replacement therapy on pancreatic β-cell function in patients with lipodystrophy.
Muniyappa R; Brown RJ; Mari A; Joseph J; Warren MA; Cochran EK; Skarulis MC; Gorden P
Diabetes Care; 2014 Apr; 37(4):1101-7. PubMed ID: 24496806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
